We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Roche Holdings Ltd AG (QX) | USOTC:RHHBY | OTCMarkets | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.45 | -1.37% | 32.32 | 32.31 | 32.33 | 32.44 | 32.18 | 32.35 | 2,504,569 | 21:07:24 |
From May 2023 to May 2024
By Maitane Sardon
Roche said that the European Commission, the EU's executive arm, has approved extending the use of its Evrysdi treatment for babies under two months diagnosed with spinal muscular atrophy.
The Swiss pharma company said Tuesday that the approval is based on interim data from an ongoing trial that showed most babies treated with Evrysdi were able to stand and walk within timeframes typical of healthy babies by 12 months of treatment, Roche said.
Evrysdi is currently approved in the EU for treating patients two months or older.
Write to Maitane Sardon at maitane.sardon@wsj.com
(END) Dow Jones Newswires
August 29, 2023 01:37 ET (05:37 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Roche (QX) Chart |
1 Month Roche (QX) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
